TY - JOUR
T1 - Immunotherapy in Breast Cancer
T2 - the New Frontier
AU - Hu, Zishuo I.
AU - McArthur, Heather L.
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.
AB - Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.
KW - Breast cancer
KW - Checkpoint inhibitors
KW - Immunotherapy
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85045449431&partnerID=8YFLogxK
U2 - 10.1007/s12609-018-0274-y
DO - 10.1007/s12609-018-0274-y
M3 - Review article
AN - SCOPUS:85045449431
SN - 1943-4588
VL - 10
SP - 35
EP - 40
JO - Current Breast Cancer Reports
JF - Current Breast Cancer Reports
IS - 2
ER -